Chaim Hurvitz's most recent trade in NRX Pharmaceuticals Inc was a trade of 287,812 Common Stock done at an average price of $1.0 . Disclosure was reported to the exchange on Oct. 21, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NRX Pharmaceuticals Inc | Chaim Hurvitz | Director | Purchase of securities on an exchange or from another person at price $ 0.99 per share. | 21 Oct 2022 | 287,812 | 287,812 | - | 1.0 | 284,934 | Common Stock |
| NRX Pharmaceuticals Inc | Chaim Hurvitz | Director | Purchase of securities on an exchange or from another person at price $ 1.08 per share. | 21 Oct 2022 | 171,780 | 459,592 | - | 1.1 | 185,522 | Common Stock |
| NRX Pharmaceuticals Inc | Chaim Hurvitz | Director | Purchase of securities on an exchange or from another person at price $ 1.10 per share. | 21 Oct 2022 | 40,408 | 500,000 | - | 1.1 | 44,449 | Common Stock |
| NRX Pharmaceuticals Inc | Chaim Hurvitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2021 | 1,436,350 | 1,436,350 | - | - | Common Stock | |
| NRX Pharmaceuticals Inc | Chaim Hurvitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2021 | 218,423 | 218,423 | - | - | Common Stock Warrant (Right to buy) | |
| NRX Pharmaceuticals Inc | Chaim Hurvitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2021 | 208,443 | 208,443 | - | - | Common Stock |